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Objectives
To comprehensively evaluate the efficacy and safety of the
hexanic extract of Serenoa repens (HESr, Permixon; Pierre
Fabre Medicament, Castres, France), at a dose of 320 mg
daily, as monotherapy for the treatment of lower urinary tract
symptoms associated with benign prostatic hyperplasia
(LUTS/BPH).
Materials and methods
We conducted a systematic review and meta-analysis of
randomised controlled trials (RCTs) and prospective
observational studies in patients with LUTS/BPH identified
through searches in Medline, Web of Knowledge (Institute
for Scientific Information), Scopus, the Cochrane Library, and
bibliographic references up to March 2017. Articles studying
S. repens extracts other than Permixon were excluded. Data
were collected on International Prostate Symptom Score
(IPSS), maximum urinary flow rate (Qmax), nocturia, quality
of life, prostate volume, sexual function, and adverse drug
reactions (ADRs). Data obtained from RCTs and
observational studies were analysed jointly and separately
using a random effects model. A sub-group analysis was
performed of studies that included patients on longer-term
treatment (≥1 year).
Results
Data from 27 studies (15 RCTs and 12 observational
studies) were included for meta-analysis (total N = 5 800).
Compared with placebo, the HESr was associated with 0.64
(95% confidence interval [CI] 0.98 to 0.31) fewer voids/
night (P < 0.001) and an additional mean increase in Qmax
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of 2.75 mL/s (95% CI 0.57 to 4.93; P = 0.01). When
compared with a-blockers, the HESr showed similar
improvements on IPSS (weighted mean difference [WMD]
0.57, 95% CI 0.27 to 1.42; P = 0.18) and a comparable
increase in Qmax to tamsulosin (WMD 0.02, 95% CI 0.71
to 0.66; P = 0.95). Efficacy assessed using the IPSS was
similar after 6 months of treatment between the HESr and
5a-reductase inhibitors (5ARIs). Analysis of all available
published data for the HESr showed a mean improvement
in IPSS from baseline of 5.73 points (95% CI 6.91 to
4.54; P < 0.001). HESr did not negatively affect sexual
function and no clinically relevant effect was observed on
prostate-specific antigen. Prostate volume decreased slightly.
Similar efficacy results were seen in patients treated for
≥1 year (n = 447). The HESr had a favourable safety profile,
with gastrointestinal disorders being the most frequent ADR
(mean incidence of 3.8%).
Conclusion
The present meta-analysis, which includes all available RCTs
and observational studies, shows that the HESr (Permixon)
reduced nocturia and improved Qmax compared with placebo
and had a similar efficacy to tamsulosin and short-term 5-
ARI in relieving LUTS. HESr (Permixon) appears to be an
efficacious and well-tolerated therapeutic option for the long-
term medical treatment of LUTS/BPH.
Keywords
systematic review, meta-analysis, LUTS/BPH, hexanic extract,
Serenoa repens, Permixon
Introduction
LUTS are prevalent in adult men and are often associated
with the presence of BPH [1]. LUTS associated with BPH
(LUTS/BPH) is a troublesome condition that can have a
significant negative impact on patients’ quality of life (QOL)
[2].
A range of treatment options are currently available for
LUTS/BPH, including medical treatment and surgical
interventions; watchful waiting might also be considered a
management option in men whose symptoms are not overly
bothersome and who are considered at low risk of clinical
progression [3]. Medical therapies used to treat LUTS/BPH
include a1-blockers, 5a-reductase inhibitors (5ARIs),
muscarinic receptor antagonists, phosphodiesterase 5
inhibitors, and phytotherapy [3], several of which can be used
in combination.
Serenoa repens (S. repens) is the phytotherapeutic agent most
commonly used to treat LUTS/BPH and is the most
thoroughly studied, although systematic reviews and meta-
analyses of S. repens data from RCTs have reported
somewhat contrasting results. In a Cochrane meta-analysis,
Tacklind et al. [4] concluded that S. repens does not improve
LUTS or maximum urinary flow rate (Qmax) compared with
placebo in men with BPH. However, a previous meta-analysis
from the same group of researchers showed that S. repens
improves urological symptoms and flow measures compared
to placebo and that it produces similar improvement in
urinary tract symptoms and urinary flow to finasteride, with
fewer adverse events (AEs) [5,6]. One explanation for these
apparently contradictory results is that the earlier meta-
analysis mainly included randomised controlled trials (RCTs)
investigating a specific brand of S. repens (Permixon; Pierre
Fabre Medicament, Castres, France) whilst the subsequent
meta-analysis included several brands. As the composition of
S. repens extracts varies significantly between manufacturers
[7] and as different extraction techniques may affect the
composition and biological activity of different brands of
S. repens [8], it is possible that the greater focus on
Permixon in the earlier meta-analysis and the inclusion of a
broader range of products in the second led to the different
results.
Meta-analysis on plant extracts should therefore only include
phytotherapeutic agents that have used the same validated
extraction technique and/or have the same level of active
ingredients as the pharmacokinetic properties can vary
significantly, a fact which is clearly reflected in the 2017
European Association of Urology (EAU) Guidelines [3]. The
two systematic reviews and meta-analyses that have focused
exclusively on the hexanic extract of S. repens (HESr,
Permixon) [9,10] are examples of this approach. The earlier
review by Boyle et al. [9] showed significant improvements in
Qmax, nocturia, and IPSS with the HESr, whilst the more
recent meta-analysis of RCTs, which included the latest
publications, came to similar conclusions [10]. However, both
meta-analyses drew primarily on results from RCTs. The
inclusion of data from observational studies, which are more
often performed under conditions of usual practice and that
include a wide range of patients, can provide relevant,
complementary information in systematic reviews [11–15].
The objective of the present study was to carry out an
exhaustive systematic review and meta-analysis of all available
RCTs and prospective observational studies performed with
the HESr (Permixon) and to provide a comprehensive
overview of its efficacy and tolerability for the medical
treatment of LUTS/BPH.
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Materials and Methods
Search Strategy
The meta-analysis was performed according to a pre-specified
protocol guided by standards established for the Meta-
analysis Of Observational Studies in Epidemiology (MOOSE)
[16]. The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) recommendations [17] were
used to guide reporting of the study.
Data searches were carried out up to April 2017 in four
electronic databases (Medline, Web of Knowledge [Institute
for Scientific Information], Scopus, and The Cochrane
Library) to identify eligible studies published from inception
through to March 2017.
Search terms included ‘Serenoa repens’, ‘saw palmetto’, ‘Sabal
serrulata’, ‘Permixon’, ‘benign prostatic hyperplasia’, ‘BPH’,
‘prostatic adenoma’, ‘prostatic hypertrophy’, ‘lower urinary
tract symptom’, and ‘LUTS’, which were combined with
terms such as ‘efficacy’, ‘tolerability’, and ‘outcome’. Reference
lists of identified articles and published reviews were also
hand searched.
Eligibility Criteria
We included studies that assessed the efficacy and/or safety of
the HESr (Permixon) at a daily dosage of 320 mg in patients
with LUTS/BPH. Articles were included for review if it was
clearly indicated that the product studied was the HESr
(Permixon) or if that information could be easily deduced
from the content. Study designs considered eligible for review
included RCTs, non-randomised controlled trials, case-control
studies, and prospective observational studies if they included
data on the selected outcomes. There were no limitations on
publication language. Theses, governmental reports and
clinical surveys were excluded, as were clinical cases, studies
on corpses, in vitro studies, or studies in populations other
than human adult males.
Study Selection and Data Extraction
Two independent reviewers examined the results of the
literature search and classified studies as being potentially
suitable for inclusion based first on titles and abstracts, then
on full texts. Disagreements about the relevance of individual
studies were resolved in discussion with a third reviewer. The
final list of articles for data extraction was agreed upon in
discussions amongst the study team.
Two reviewers working independently and using a
standardised form extracted data from the articles. The two
sets of extracted data were then compared by one of the
reviewers and discrepancies were resolved by either referring
to the original source text and/or by discussion amongst the
reviewers, with the assistance of a third reviewer if necessary.
Data were extracted on study setting and design, study
population, treatment characteristics (dose and duration), and
outcomes, as described below. In the case of one
observational study [18], only sub-groups of patients with
comparable baseline characteristics in terms of LUTS severity
were included when comparing results between the HESr and
a-blockers or 5ARIs, to ensure comparability of results.
Outcomes Assessed
Data were extracted on the following outcomes: IPSS, Qmax
(mL/s), nocturia, QOL (IPSS item 8, on a 0–6 scale), prostate
volume, and sexual function. A decrease of ≥3.1 points on the
IPSS was considered to represent a clinically relevant
difference, as previously reported [19]. A subgroup analysis of
studies reporting data for ≥1 year of treatment was also
carried out to explore longer-term effects of treatment. A
sub-group analysis was also performed by using a random
effects model to test results for observational studies and
RCTs separately. Results for the two types of study were then
compared using a chi-squared test for subgroup differences.
In the case of safety data, we differentiated between adverse
drug reactions (ADR) and AEs based on how the outcome
was reported by the original study. An ADR was defined as a
response to a drug that is noxious and unintended, and
which occurs at doses normally used in man for prophylaxis,
diagnosis, or therapy of disease or for modification of
physiological function. An AE was defined as any untoward
medical occurrence in a patient or clinical investigation
subject administered a pharmaceutical product and which
does not necessarily have a causal relationship with the
treatment [20].
Quality Assessment
As both observational studies and RCTs were included in the
review, a quality indicator was sought which was suitable for
both study types. The Quality Index (QI) was developed by
Downs and Black [21], and is appropriate for assessing
randomised and non-randomised studies. It consists of 26
items covering reporting, external validity, bias, confounding,
and sample size, and has been shown to have good internal
consistency, test–retest and inter-rater reliability. The score
range for the QI is 0–27, with higher scores indicating better
quality. Assessment of study quality was carried out by one
reviewer with support from another reviewer if needed.
Statistical Methods
Continuous outcomes (IPSS, nocturia, QOL and Qmax) were
expressed as mean pre–post treatment differences when
assessing the effect of the HESr alone or as the difference
between pre- and post-treatment values when comparing the
© 2018 The Authors
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HESr with placebo or other active treatments. For
dichotomous outcomes (ADR), proportions were used to
assess the effect of the HESr. Meta-analysis was performed
using a random effects model to summarise outcomes from
the studies included [22]. When standard deviations (SDs) or
standard errors (SEs) for mean differences were not provided
in the original publication, they were imputed from other
studies included in the analysis. For all outcomes studied,
sensitivity analysis was performed by excluding studies that
did not provide either SDs or SEs.
The Woolf statistic [23], from which we calculated the I2
statistic, was used to analyse the degree of heterogeneity
amongst studies. If significant heterogeneity due to outliers
was found, secondary analysis was performed by sequentially
removing studies considered as outliers (standardised residual
absolute value >2) and meta-analyses refitted until no studies
were considered outliers. When assessing the size of effect
attributable to the HESr, we distinguished between
observational studies and RCTs by performing a random
effects model meta-analysis within each group. Summarised
results were then compared using a Z-test.
Results are displayed as forest plots, while the presence of
publication bias was explored using funnel plots [24]. If
publication bias was suspected, additional sensitivity analysis
was performed by removing the studies potentially associated
with this bias and repeating the analysis. The results of the
analysis were reviewed and interpreted independently by all
authors.
For all analyses, 95% CIs are reported and test results are
considered significant for P < 0.05. All analyses were
performed in R (version 3.2.2) [25] using the ‘meta’ [26] and
‘metafor’ [27] packages (R, R Foundation for Statistical
Computing, Vienna, Austria).
Results
Data for meta-analysis were extracted from a total of 27 studies,
of which 15 [28–42] were RCTs and 12 [18,43–53] were
observational studies. The selected studies included 5 800
patients corresponding to: Permixon (n = 3 926); a-blockers
(n = 775; tamsulosin [n = 377], unspecified [n = 398]); 5ARIs
(n = 578; finasteride [n = 484], unspecified [n = 94]); placebo
(n = 301); control group (n = 190); and gestonorone caproate
(n = 30). The subgroup analysis of studies reporting ≥1 year of
treatment included three clinical trials [40, 50, 51] with data
from 447 patients. The PRISMA trial flow diagram for the
systematic review is presented in Fig. 1.
The key characteristics of the studies included in the meta-
analysis are shown in Tables 1 and 2. Of the 27 studies
included, one RCT [35] and one observational study [45]
were used solely for information on ADR due to a lack of
precision in the efficacy data. Articles were published between
1983 [28] and 2016 [18] with sample sizes ranging from 10
[43] to 1 713 [18]. Study duration ranged from 1 month [36]
to 60 months [50], although the most frequent duration was
3 months (10 studies). In most of the comparative studies,
the comparator used was placebo [28–32,34,36], although
some studies compared the HESr to 5ARIs [18,37] or
a-blockers [18,40,42], whilst two studies [38,39] compared
different forms of administration of the HESr. Scores on the
Downs and Black QI (DBQI) ranged from 3 [46] to 25 [40],
with a mean of 15 for the RCTs and 11 for the observational
studies.
Supporting information for the most relevant outcomes,
including funnel plots of all analysed outcomes and, where
appropriate, the results of sensitivity analysis, is shown in
Figs S1–S11.
Permixon Compared to Placebo
All studies included in this analysis were RCTs and of
moderate quality, according to the DBQI (score between 6
and 17).
Figure 2 shows the forest plots for efficacy data of the HESr in
comparison with placebo for nocturia and Qmax. The meta-
analysis (Fig. 2a) shows a benefit of 0.64 (95% CI 0.98 to
0.31) fewer voids/night for the HESr (P < 0.001). Data on
Qmax were available from four studies [28,29,32,36], with the
HESr providing an additional benefit over placebo of 2.75 mL/
s (95% CI 0.57 to 4.93; P = 0.014; Fig. 2b). No heterogeneity
was observed. Funnel plots of the nocturia and Qmax analysis
suggest no publication bias (Figs S1 and S2, respectively).
Permixon Compared to a-Blockers
Three studies [18,40,42], two RCTs and one observational
study, reported data on IPSS; all were of high quality based
on their DBQI scores (between 19 and 25).
Figure 3a shows a difference in effect between HESr and
a-blockers on IPSS of 0.57 points, although the difference was
not statistically significant (95% CI 0.27 to 1.42; P = 0.18).
The result was almost identical when data from a study
identified as an outlier was excluded (WMD 0.3, 95% CI
0.29 to 0.89; P = 0.31; Fig. S3). When only data from RCTs
was used, the results were similar, with no statistically
significant difference between arms (P = 0.35).
The effect of the HESr and tamsulosin on Qmax and prostate
volume was compared using data from two RCTs [40,42]. No
statistically significant differences were found for either
endpoint (P = 0.95 for Qmax, Fig. 3b; and P = 0.34 for
prostate volume, Fig. 3c). Likewise, no statistically significant
differences were found between the HESr and a-blockers in
terms of effect on PSA (P = 0.60, Fig. 3d).
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Permixon Compared to 5ARIs
Two studies [18,37], with a DBQI score of 19 and 21,
respectively, compared the effects of 5ARIs and the HESr on
IPSS outcomes. There was no statistically significant
difference between the treatments at the 6-month follow-up
(difference of 0.46 points, 95% CI 0.41 to 1.34; P = 0.30;
Fig. 4a). In the same studies, PSA values showed a statistically
significant reduction (P < 0.001) with 5ARIs compared with
stable PSA values with the HESr (Fig. 4b). No heterogeneity
was observed between the studies for either outcome
(I2 = 0%, P > 0.49).
Permixon, Change from Baseline
Figure 5 shows change from baseline with the HESr over a
range of outcomes. The mean IPSS (Fig. 5a) improved by
5.73 points (95% CI 6.91 to 4.54; P < 0.001), with
symptom relief seen both in patients with moderate–severe
symptoms and in those with mild symptoms [53]. Study
quality varied widely with the DBQI score ranging between
5 and 25. There was no significant difference between the
results obtained using data from RCTs (WMD 5.76, 95%
CI 7.00 to 4.52; P < 0.001) and those obtained using
data from observational studies (WMD 5.70; 95% CI
Full text articles excluded (n= 152):  
- Review articles (n= 52)  
- Not BPH (n=34)  
- Permixon not clearly 
identified (n=33) 
- Letters/poster (n= 8)  
- Permixon in combination 
with other treatment (n=5)  
- Duplicate results (n=2)  
- Post-hoc analysis (n=2)  
- Study presenting results for 
several diseases (n=1)  
- Other (n=15) 
Records excluded  
(n=683)
Studies included in 
quantitative synthesis 
(n=27) 
Full text articles 
assessed for eligibility 
(n=179 )
Records screened 
(n=862)
Records identified from 
electronic databases 
(n=1432)
Records after duplicates removed 
(n=862) 
Additional records identified (n=46): 
- ClinicalTrials.gov (n=11) 
- Conference websites (n=9) 
- Records identified from hand-
searching of reference lists (n=26) 
RCT 
(n=15) 
Observational studies 
(n=12)
≥1 year treatment period 
studies (n=3)
Figure 1 PRISMA flow chart.
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7.67 to 3.72; P < 0.001; [test for subgroup differences, P
= 0.96]).
Funnel plot analysis suggested a potential publication bias
(Fig. S4), although after excluding outliers the mean
improvement in IPSS was 5.38 points (95% CI 6.36 to
4.39; P < 0.001; Fig. S5). The funnel plot for the latter
analysis shows a symmetric distribution, although a potential
publication bias cannot be completely discounted (Fig. S6).
Analysis of Qmax data (Fig. 5b) indicated that the HESr was
associated with an increase of 2.89 mL/s (95% CI 1.92 to
3.85; P < 0.001) from baseline, although the funnel plot
indicates possible publication bias (Fig. S7). When analysing
the studies with complete data, an improvement of 2.26 mL/s
(95% CI 1.80 to 2.71; P < 0.001) was seen with no
heterogeneity (Fig. S8) or publication bias (Fig. S9).
The results for nocturia (Fig. 5c) showed a mean reduction
from baseline of 1.56 voids/night with the HESr (95% CI
2.16 to 0.97; P < 0.001). No publication bias was
observed. The reduction in number of voids/night was 1.58
(95% CI 2.12 to 1.04; P < 0.001) when outliers were
excluded.
For QOL (Fig. 5d), which was assessed using question 8 of
the IPSS, the HESr was associated with an improvement of
1.07 points (95% CI 1.28 to 0.87; P < 0.001). A similar result
was seen after exclusion of outliers (overall reduction of 1.03
points, 95% CI 1.25 to 0.80; P < 0.001).
For prostate volume (Fig. 5e), HESr was associated with a
statistically significant reduction of 2.93 mL (95% CI
4.58 to 1.28; P < 0.001) corresponding to a mean
reduction of 6.8% from baseline. Funnel plot analysis
showed no publication bias. When outliers were excluded,
the decrease was of 2.36 mL (95% CI 3.73 to 0.99;
P < 0.001).
Change in PSA was assessed in five studies [18,37,40,49,51].
There was a clinically non-significant mean change of
0.17 ng/mL (95% CI 0.07 to 0.27) when analysing data
that showed no heterogeneity (I2 = 1%, P = 0.403;
Fig. S10).
Sexual function was assessed in four studies [37,40,42,51]
using the Male Sexual Function four-item questionnaire, with
meta-analysis showing no relevant effect of the HESr on
sexual function (P = 0.64; Fig. S11).
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When comparing the results between observational studies
and RCTs, it was confirmed that there were no statistically
significant differences between the two types of study when
analysing IPSS, Qmax and QOL outcomes. Statistically
significant differences between study types were found for
nocturia and prostate volume.
Change from Baseline to End of Treatment with
Permixon in Studies with ≥1 Year of Treatment
Figure 6 shows the forest plots for change from baseline with
HESr treatment for patients treated for ≥1 year. The studies
selected for this analysis had treatment and follow-up periods
of 1 [40], 2 [51,53] and 5 [50] years, with DBQI scores
between 5 and 25. However, the Djavan et al. [53] study only
included patients with mild IPSS, who do not usually receive
medical treatment [3]. As that meant it investigated a
clinically different population from the other studies, it was
excluded from this sub-group analysis.
Meta-analysis of change in outcomes from baseline showed a
mean improvement in IPSS (Fig. 6a) of 6.06 points (95% CI
8.00 to 4.13; P < 0.001), or 4.85 points (95% CI 5.76
to 3.94; P < 0.01) after exclusion of outliers. There was an
increase in Qmax (Fig. 6b) of 2.29 mL/s (95% CI 0.89 to 3.69;
P < 0.001), or 1.81 mL/s (95% CI 1.27 to 2.36; P < 0.01) after
excluding outliers, and an improvement in QOL, measured
using IPSS item 8, of 1.31 points (95% CI 1.46 to 1.16;
P < 0.001; Fig. 6c), with no heterogeneity. Prostate volume
decreased by 5.37 mL (95% CI 10.34 to 0.41; P = 0.034)
corresponding to a mean reduction of 6.8% (Fig. 6e). When
the two studies with complete data were analysed, the
decrease in prostate volume was 3.32 mL (P = 0.18).
Change in PSA was measured in two of the three studies
[40,51] and no clinically significant change was observed
when analysing data that showed no heterogeneity (I2 = 0%,
P = 0.51).
ADRs
The incidence of ADRs associated with the HESr was low.
Only four ADRs had a mean incidence of >1% (Table 3).
Gastrointestinal disorders were reported by 3.8% of patients
and nausea and vomiting each had a mean incidence of 2.6%.
Long-term treatment with the HESr was safe and well-
tolerated. In the studies with 2 [51] and 5 [50] years of
treatment, tolerability was reported to be good and none of
the ADRs registered were considered by investigators to be
associated with the HESr treatment. The third long-term
treatment study [40] reported AEs and showed a marked
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Figure 4 Forest plots of studies comparing Permixon with 5ARIs on (a) IPSS and (b) PSA. PMX, hexanic extract of Serenoa repens (Permixon).
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reduction in the incidence of ejaculation disorders with the
HESr in comparison with tamsulosin (P = 0.001).
Discussion
This comprehensive systematic review and meta-analysis of
outcomes with Permixon, a HESr, confirms that the HESr has
a positive effect on the endpoints most commonly used to
assess treatment efficacy in patients with LUTS/BPH.
Effectively, analysis of data from RCTs showed superiority for
the HESr over placebo on the analysed outcomes and
equivalent efficacy to a-blockers on IPSS and Qmax
improvement. The HESr was also found to have equivalent
efficacy to short-term treatment (6 months) with 5ARIs in
terms of impact on the IPSS.
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Figure 6 Forest plots of outcomes for Permixon studies of ≥1 year: efficacy data for (a) IPSS, (b) Qmax, (c) QOL (IPSS item 8), and (d) prostate volume.
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When compared with baseline values, Permixon was
associated with a clinically significant improvement in the
IPSS, an increase in Qmax and an improvement in patient
QOL. The HESr was also associated with a slight decrease in
prostate volume. There was no evidence of a negative impact
on sexual function and treatment benefits were accompanied
by a very low rate of ADRs, indicating excellent tolerability.
Our present findings are similar to those reported in the two
other systematic reviews and meta-analysis of Permixon
performed to date [9,10]. The authors of those reviews also
reported that the HESr was associated with a clinically
significant reduction in IPSS, a mean increase in Qmax, and
fewer episodes of nocturia, and that it showed similar efficacy
to tamsulosin and short-term finasteride in relieving LUTS
[10]. Permixon’s safety profile was also excellent, with a low
incidence of reported ADRs. In the studies that compared AEs
of the HESr and a-blockers, the most notable difference was
the higher prevalence of ejaculation disorders associated with
a-blockers [18,40,42]. This is important because, as well as
negatively impacting patients’ QOL, treatments affecting
sexual function can be associated with poorer adherence
[54,55]. Finally, the results of the long-term treatment analysis
were similar to those obtained with the whole sample,
confirming the sustained efficacy and safety of the HESr.
In an increasingly polymedicated population, such as elderly
men affected by LUTS/BPH, the availability of an effective
treatment with a very low rate of ADRs and very limited
drug interactions is of relevance. This is highlighted in the
LUTS-Fit fOR The Aged (FORTA) 2014 classification [56],
which classifies a1-blockers (tamsulosin, silodosin) as FORTA
C (careful; questionable use) in older persons and suggests
that alternatives should be sought if necessary. Other
a-blockers (alfuzosin, doxazosin, terazosin) are considered
FORTA D (avoid in older people) and the guidelines indicate
that alternatives with a better safety/efficacy profile should be
identified for elderly patients. As only the most widely used
oral drugs were included in the LUTS-FORTA classification,
the HESr and other phytotherapeutic drugs were not
evaluated.
Together with the fact that the present review contained all
available published data for Permixon, from both RCTs and
observational studies, a further strength of the study is that it
focused exclusively on one particular extract of S. repens. This
contrasts with earlier Cochrane meta-analyses, which included
different S. repens extracts and did not investigate results for
individual brands [4,57], despite evidence of differences in
composition between them [7]. It has been emphasised that
different compositions lead to differences in potency, with
Permixon showing considerably greater inhibition of
5a-reductase types I and II isoenzymes than other S. repens
extracts [58,59]. In the most recent published Cochrane meta-
analysis of S. repens extracts, it was reported that they were
no better than placebo in reducing LUTS symptoms or
nocturia, or in increasing Qmax [57]. However, the authors
acknowledged that their conclusions may not be generalisable
to proprietary products of S. repens extracts, such as
Permixon or Prostagutt forte (Dr Willmar Schwabe GmbH
& Co. KG, Karlsruhe, Germany). Interestingly, in feedback to
the full report of the Cochrane meta-analysis, Bilia et al. [4]
noted some flaws, including non-equivalence among the
different S. repens extracts and the fact that dose was not
taken into account. When assessing plant extracts, this issue
is critical; for example, the publication by Scaglione et al. [59]
found that about five-times the dose of another S. repens
extract was needed to achieve the same in vitro inhibitory
effect on the 5ARI enzyme type II as Permixon, which was
the most potent extract. One of the explanations for this
difference appears to be the content in free fatty acids of the
different brands. Composition analysis showed that Permixon
has the highest proportion of free fatty acids (>80%), whilst
the brand with the lowest amount had just 40% and there
was substantial variability among brands in general [7].
Moreover, some inaccuracies have been observed in the data
extraction for the Cochrane meta-analysis [4]. For example,
mean urine flow data was registered instead of Qmax data in
two studies [30,34] and the number of patients reported for
Cukier et al. [31] differed from the number reported in the
article. The conclusions of the Cochrane meta-analysis should
therefore be treated with caution.
The current European LUTS/BPH EAU guidelines [3]
propose that different brands of phytotherapy should be
assessed individually because differences in potency mean
that results cannot be extrapolated from one brand to
another. In relation to this, a recent European Medicines
Agency (EMA) report concluded that ‘only the hexanic
extract of the fruit of S. repens is considered to be supported
by sufficient evidence to support the use as a well-
established medicinal product with recognized efficacy and
acceptable safety’ [60]. The ethanolic and the supercritical
CO2 extracts of S. repens do not seem to have enough
clinical evidence to support their use as a medicinal product
[60]. In the case of Permixon, in vitro and in vivo studies
have evidenced its mechanism of action, which includes an
anti-inflammatory effect [41,42,61,62], 5a-reductase
inhibition [58,63,64], and inhibition of growth factors in the
prostatic tissue [64].
Table 3 Rates of ADRs associated with Permixon (only ADRs with an
incidence >1% are shown).
ADR Mean % (95% CI)
Gastrointestinal disorders 3.8 (2.2–6.5)
Nausea and vomiting 2.6 (0.8–8.6)
Hypertension 1.2 (0.2–8.0)
Tinnitus 1.2 (0.2–8.0)
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One of the limitations of the present study was the quality of
some of the original studies included in the meta-analysis.
This was addressed to some extent by analysing RCTs and
observational studies separately, with no clinically relevant
differences observed in the most important outcomes between
the two types of study. The relatively limited follow-up
duration of several of the studies might also be considered a
limitation, although it was sufficient to register clinical
changes in the outcomes evaluated. The sub-analysis of data
from studies with a treatment period of ≥1 year, in which we
found similar results to those from the analysis using
complete data, also addressed this point. Moreover, the mean
follow-up period of the studies included in the complete
analysis was similar to that used in recent trials to study the
efficacy of various treatments for LUTS/BPH [65–67]. Finally,
we also observed some heterogeneity between studies. This
was taken into account by carrying out sensitivity analysis
which showed that, in general, the exclusion of outliers did
not substantially affect the results of the different meta-
analyses. The use of a random effects model approach to
meta-analysis likewise takes the variability between studies
into account and provides a more conservative estimate of
effect.
In conclusion, this exhaustive systematic review and meta-
analysis of studies assessing Permixon in the treatment of
LUTS/BPH found a positive effect over and above placebo on
the most relevant outcomes. The mean 5.73 points
improvement from baseline in the IPSS with the HESr
treatment is higher than the minimum 3.1 points that is
deemed necessary to be perceived as a clinically meaningful
improvement by the patient [19]. Moreover, the available
studies comparing Permixon and a-blockers and short-term
5ARIs showed that the HESr led to similar levels of
improvement on the IPSS, with a better tolerability profile.
Permixon could therefore be a valid therapeutic option to
consider for first-line treatment of LUTS/BPH. The results of
the present meta-analysis suggest that the HESr should be
considered as a treatment option in the next update of LUTS
treatment guidelines.
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